Based on our current knowledge, the use of anti-TNFR2 in therapy will have to be context-dependent, with TNF-α levels in the tumor surroundings and the time of exposure to this cytokine (depending on the tumor type and disease stage) being potentially the most crucial factors to consider when using such agents. This evidence concerns the gene TNFRSF1B and neoplasm.